Espen A. Haavardsholm
Center manager REMEDY https://orcid.org/0000-0002-1427-4745
![](https://remedy-senter.no/templates/yootheme/cache/db/NIC-Espen-Haavardsholm-2-db789404.jpeg)
Education
- Doctor at the University of Oslo (professional study in medicine)
- Doctoral degree at the Department of Clinical Medicine, University of Oslo
Position
- Head of Centre, Research Center for Treatment in Rheumatology and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital
- Head of department for research and innovation, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital
- Professor II, Department of Clinical Medicine, University of Oslo
Field of interest
- Rheumatology
- Musculoskeletal diseases
- Osteoarthritis
- Randomized clinical trials
- Register studies
- Image diagnostics
- Translational research
Other
- President, Scandinavian Society of Rheumatology
- Chairman, Stiftelsen Scandinavian Rheumatology Association
- Board member, Norwegian Rheumatology Association
visiting address
Diakonhjemmet hospital
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo
Postal address
Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo
Projects
ARCTIC FORWARD
10-year follow-up of patients with rheumatoid arthritis who received structured treatment-to-target therapy in the early disease phase.
Project Manager:
Siri LillegravenARCTIC REWIND
10-year follow-up of patients with rheumatoid arthritis who received structured treatment-to-target therapy in the early disease phase.
Project Manager:
Espen A. HaavardsholmBIKE
Biopsies of synovitis in the knee joint from patients with RA and OA
Project Manager:
Hilde Berner HammerMERINO
Methotrexate in the treatment of erosive hand osteoarthritis
Project Manager:
Ida Bos-HaugenProject Manager:
Siri LillegravenMinJIA
Strategies for personalized treatment of juvenile idiopathic arthritis (JIA)
Project Manager:
Berit FlatøNOR-CACTUS
Comparison of treatment strategies in carpal tunnel syndrome
Project Manager:
Hilde Berner HammerProject Manager:
Tore K. KvienNOR DRUM
The Norwegian study for therapeutic drug monitoring
Project Manager:
Espen A. HaavardsholmNOR Flare
Distance follow-up of patients with rheumatoid arthritis
Project Manager:
Anne Therese TveterNOR Sprint
Follow-up of newly diagnosed patients with psoriatic arthritis with and without imaging
Project Manager:
Siri LillegravenNor-vaC
Immunological response to COVID-19 vaccine in patients on immunosuppressive treatment
Project Manager:
Guro Løvik GollNORTH STAR
The Nordic study of strategy tests and registries for rheumatic diseases
Project Manager:
Espen A. HaavardsholmPICASSO
Treatment of painful inflammatory carpometacarpal-1 osteoarthritis with intra-articular steroids, saline or occupational therapy
Project Manager:
Ida K. Bos-HaugenRA DRUM
Therapeutic drug monitoring in patients with rheumatoid arthritis (RA-DRUM)
Project Manager:
Silje Watterdal SyversenReMonit
remote monitoring of patients with spondyloarthritis
Project Manager:
Nina ØsteråsRIMRA
Rheumatic immune-related side effects in patients treated with immunotherapy
Project Manager:
Marte Schrumpf HeibergSQUEEZE
Maximizing the effect of prescription drugs in rheumatoid arthritis
Project Manager:
Espen A. HaavardsholmProject Manager:
Silje Watterdal SyversenPublications
Publications taken from the National Science Archive (NVA):
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomized controlled, non-inferiority trial
The Lancet Rheumatology
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyzes of the randomised, controlled NOR-DRUM trials
The Lancet Rheumatology
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
RMD Open
Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomized controlled trial
Annals of the Rheumatic Diseases
Follow-Up of Patients With Axial Spondyloarthritis in Specialist Health Care With Remote Monitoring and Self-Monitoring Compared With Regular Face-to-Face Follow-Up Visits (the ReMonit Study): Protocol for a Randomized, Controlled Open-Label Noninferiority Trial
JMIR Research Protocols
Effect of tapered versus stable treatment with tumor necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
Annals of the Rheumatic Diseases
Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010–2019)
BMC Health Services Research
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomized controlled NORD-STAR trial
Annals of the Rheumatic Diseases
Calprotectin, a sensitive marker of inflammation, is robustly assessed in plasma from patients with early or established rheumatoid arthritis by use of different laboratory methods
Scandinavian Journal of Clinical and Laboratory Investigation
Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and Excellent Disease Control
Journal of the American Medical Association (JAMA)
Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomized controlled trial
The Lancet Rheumatology
Using observational study data as an external control group for a clinical trial: an empirical comparison of methods to account for longitudinal missing data
BMC Medical Research Methodology
Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study
RMD Open
Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs
BMC Health Services Research
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Journal of the American Medical Association (JAMA)
Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.
Arthritis Research & Therapy
12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: Achievements of the urate target levels and predictors of obtaining this target
RMD Open
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial
Journal of the American Medical Association (JAMA)
Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy
RMD Open
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Journal of the American Medical Association (JAMA)
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)
Trials
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial
The BMJ
Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study
Annals of the Rheumatic Diseases
The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial
BMC Musculoskeletal Disorders
Rheumatoid Arthritis Patients, Both Newly Diagnosed and Methotrexate Treated, Show More DNA Methylation Differences in CD4+ Memory Than in CD4+ Naïve T Cells
Frontiers in Immunology
Assessing synovitis in the hands in patients with rheumatoid arthritis by ultrasound: an agreement study exploring the most inflammatory active side from two Norwegian trials
Arthritis Research & Therapy
Swollen, but not tender joints, are independently associated with ultrasound synovitis: Results from a longitudinal observational study of patients with established rheumatoid arthritis
Annals of the Rheumatic Diseases
Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial
Journal of Internal Medicine
Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
RMD Open
Comparative analyzes of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyzes from the ARCTICstudy
RMD Open
The impact of ultrasound on the use and efficacy of intraarticular glucocorticoid injections in early rheumatoid arthritis: Secondary analyzes from a randomized trial examining the benefit of ultrasound in a clinical tight control regimen
Arthritis & Rheumatology
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy
Arthritis Research & Therapy
Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: Associations to future good radiographic and physical outcomes
Annals of the Rheumatic Diseases
Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: Study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study
Trials
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
The Lancet
Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria
Annals of the Rheumatic Diseases